

Table S1. Time variation of HMOs concentrations according to Secretor status of women followed on Brazilian cohort. Rio de Janeiro, Brazil (n=101).

HMOs (mmol/L)	Secretors women – median (IQR) Days postpartum (n)			Non-Secretors women – median (IQR) Days postpartum (n)		
	2-8 (n=46)	28-50 (n=68)	88-119 (n=42)	2-8 (n=6)	28-50 (n=7)	88-119 (n=4)
	Fucosylated or sialylated lactose					
2'FL	5.42 (4.20-6.64)	5.18 (3.65-5.96)	4.38 (3.50-6.26)	0.01 (0.01-0.01)	0.03 (0.00-0.05)	0.03 (0.00-0.06)
3FL	0.28 ^y (0.19-0.46)	0.36 ^z (0.28-0.90)	2.24 ^{yz} (0.36-5.29)	0.13 (0.06-0.14)	0.16 (0.13-0.27)	1.02 (0.64-2.68)
DFLac	0.27 ^y (0.21-0.35)	0.39 ^z (0.31-0.52)	0.45 ^{yz} (0.39-0.60)	0.07 (0.01-0.13)	0.05 (0.03-0.07)	0.05 (0.01-0.10)
3'SL	0.32 ^y (0.25-0.48)	0.39 ^z (0.29-0.62)	0.55 ^{yz} (0.44-0.70)	0.20 (0.11-0.25)	0.33 (0.25-0.40)	0.35 (0.17-0.50)
6'SL	0.39 ^{xy} (0.22-0.55)	0.64 ^{xz} (0.49-0.93)	0.51 ^{yz} (0.39-0.74)	0.25 (0.23-0.55)	0.55 (0.43-0.89)	0.41 (0.31-0.59)
	Non-fucosylated, non-sialylated HMOs					
LNT	1.32 (1.02-1.92)	1.39 (1.03-1.96)	1.40 (1.09-1.72)	2.91 (2.47-3.33)	1.89 (1.53-2.49)	0.97 (0.81-1.07)
LNnT	0.58 ^x (0.30-1.15)	0.27 ^{xz} (0.17-0.41)	0.36 ^z (0.17-0.61)	0.62 (0.51-1.15)	0.30 (0.19-0.43)	0.26 (0.19-0.34)
LNH	0.06 ^y (0.03-0.11)	0.08 ^z (0.05-0.15)	0.06 ^{yz} (0.04-0.09)	0.11 (0.08-0.13)	0.08 (0.08-0.11)	0.07 (0.04-0.09)
	Fucosylated, non-sialylated HMOs					
LNFP I	2.85 ^x (2.27-3.49)	1.72 ^{xz} (1.06-2.42)	0.82 ^z (0.53-1.63)	0.10 (0.07-0.11)	0.12 (0.10-0.13)	0.13 (0.10-0.14)
LNFP II	0.75 ^y (0.59-1.02)	1.08 ^z (0.81-1.40)	1.55 ^{yz} (1.39-2.05)	2.17 (1.93-2.62)	2.52 (2.27-2.95)	3.37 (2.98-3.71)
LNFP III	0.08 ^x (0.07-0.12)	0.07 ^{xz} (0.05-0.10)	0.04 ^z (0.02-0.06)	0.08 (0.07-0.13)	0.08 (0.05-0.09)	0.05 (0.03-0.08)
DFLNT	1.54 ^y (1.00-1.85)	1.55 ^z (0.98-1.87)	1.27 ^{yz} (1.00-1.63)	0.30 (0.28-0.44)	0.39 (0.16-0.68)	0.92 (0.65-1.11)
FLNH	0.12 ^y (0.06-0.16)	0.15 ^z (0.08-0.23)	0.10 ^{yz} (0.07-0.14)	0.03 (0.02-0.08)	0.08 (0.04-0.13)	0.08 (0.07-0.10)
DFLNH	0.14 (0.06-0.22)	0.17 (0.10-0.26)	0.13 (0.05-0.21)	0.02 (0.01-0.03)	0.02 (0.01-0.03)	0.02 (0.01-0.09)
	Non-fucosylated, sialylated HMOs					
LSTb	0.08 (0.06-0.11)	0.10 (0.07-0.13)	0.07 (0.05-0.11)	0.18 (0.13-0.18)	0.16 (0.14-0.19)	0.11 (0.07-0.18)
LSTc	0.80 ^x (0.64-0.97)	0.27 ^{xz} (0.19-0.36)	0.11 ^z (0.07-0.16)	0.65 (0.43-0.71)	0.12 (0.10-0.35)	0.03 (0.02-0.04)
DSLNT	0.58 ^x (0.39-0.73)	0.30 ^{xz} (0.12-0.41)	0.18 ^z (0.03-0.30)	0.69 (0.43-0.86)	0.12 (0.07-0.39)	0.10 (0.02-0.27)
DSLNH	0.22 ^{xy} (0.12-0.29)	0.22 ^{xz} (0.15-0.32)	0.09 ^z (0.05-0.13)	0.16 (0.10-0.22)	0.28 (0.16-0.47)	0.09 (0.06-0.11)
	Fucosylated, sialylated HMOs					
FDSLNH	0.06 ^y (0.03-0.11)	0.16 ^z (0.08-0.28)	0.14 ^{yz} (0.09-0.23)	0.12 (0.09-0.16)	0.54 (0.38-0.63)	0.44 (0.21-0.77)
Total	16.88 (15.98-17.54)	15.58 (15.06-16.55)	16.93 (15.44-17.50)	9.68 (9.61-10.48)	8.97 (8.51-9.25)	9.29 (8.78-10.47)

IQR: interquartile range. ^x indicates that the HMO concentration at visit 1 is significantly different ($p < 0.05$) from the concentration at visit 2, ^y indicates that the HMO concentration at visit 1 is significantly different ($p < 0.05$) from the concentration at visit 3 and ^z indicates that the HMO concentration at visit 2 is significantly different ($p < 0.05$) from the concentration at visit 3 according to Friedman post-hoc test. . DFLac, difucosyllactose; DFLNH, difucosyllacto-N-hexaose; DFLNT, difucosyllacto-N-tetraose; DSLNH, disialyllacto-N-hexaose; DSLNT, disialyllacto-N-tetraose; FDSLNH, fucodisialyllacto-N-hexaose; FLNH, fucosyllacto-N-hexaose; HMO, human milk

Online Supplementary Material

oligosaccharide; LNFP, lacto-N-fucopentaose; LNH, lacto-N-hexaose; LNnT, lacto-N-neotetraose; LNT, lacto-N-tetraose; LSTb, sialyl-lacto-N-tetraose b; LSTc, sialyl-lacto-N-tetraose c; 2'FL, 2'-fucosyllactose; 3FL, 3-fucosyllactose; 3'SL, 3'-sialyllactose; 6'SL, 6'-sialyllactose.